Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: stellerstar who wrote (4359)	10/16/1998 10:45:00 AM
From: Prospector	Read Replies (2) \| Respond to of 5402

MAY, 9th 1994 BATTELLE TESTING NEWLY DEVELOPED ARTIFICIAL BLOOD Columbus Oh Dispatch Luce press clippings Battelle Memorial Institute scientists are working on a artificial blood compound that can carry up to four times as much oxygen as the real thing. The material<PHER-02 has been developed by Pasadena-based Sanguine Corp. Battelle researchers are working to adjust the formula. "The research part is done. We have developed a compound but we have not done the clinicle trials yet," Drees said. A Battelle official confirmed the research contract but declined further comment......... This artical was written May 9, 1994....clearly shows Battelle doesn't like to get in the media spotlight,, I also have a copy of a letter written to Dr Drees From Battelle, (this letter is located in the Sanguine Business Plan.) I will pull out a few key informational points, I beleive are very interesting. Thank you for your call of March 30, 1996 concerning our thought on the continuation of your program for developing artificial blood formulations. As you know, upon completion of you original work, we were very enthusiastic about continuing our efforts because of some ideas developed during the waning days of this phase of the program. We have filed several intellectual property development reports based on these ideas and have held them for Sanguine through the present because or our commitment to your efforts. We believe we have laid out a conservative next phase of the program to many of the technical challenges facing those trying to develope artificial bloods. While we certainly cannot guarantee success, we believe our ideas hold considerable merit for advancing the state of the industry in this field. We look forward to reinitiating this program and hope that funding can be provided for us to reduce to practice the ideas that we have documented in our files...As you know, rights to these ideas revert to Battelle if Sanguine does not continue with the current program....... This statement from Battelle makes it very clear to me that Battelle is very interested in the PHER-02 formulas... and if Sanguine doesn't do it BATTELLE will... now you know why Dr Drees is so excited about the animal trials.. This News of the first phase of the animal testing being a success is great news, because it adds to the credibility of Dr Drees.. and a big step to FDA approval... Prospector....(smilin ear to ear.....)